​

Mirum Pharmaceuticals (MIRM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MIRM Stock Forecast

Mirum Pharmaceuticals (MIRM) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $116.70, with a high of $140.00 and a low of $95.00. This represents a 27.19% increase from the last price of $91.75.

- $30 $60 $90 $120 $150 High: $140 Avg: $116.7 Low: $95 Last Closed Price: $91.75

MIRM Stock Rating

Mirum Pharmaceuticals stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 1 Strong Buy (5.56%), 17 Buy (94.44%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 17 1 Strong Sell Sell Hold Buy Strong Buy

MIRM Price Target Upside V Benchmarks

TypeNameUpside
StockMirum Pharmaceuticals27.19%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts4921
Avg Price Target$125.50$118.89$105.19
Last Closing Price$91.75$91.75$91.75
Upside/Downside36.78%29.58%14.65%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 2637---10
Feb, 2628---10
Jan, 2628---10
Dec, 2528---10
Nov, 2547---11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 04, 2026Gavin Clark-GartnerEvercore ISI$126.00$89.3740.99%37.33%
Feb 26, 2026Mani ForooharLeerink Partners$118.00$92.7827.18%28.61%
Feb 26, 2026Joe KimRBC Capital$128.00$94.1435.97%39.51%
Feb 17, 2026RBC Capital$130.00$102.8326.42%41.69%
Jan 26, 2026H.C. Wainwright$130.00$94.2937.87%41.69%
Jan 20, 2026Evercore ISI$101.00$91.1310.83%10.08%
Jan 13, 2026H.C. Wainwright$102.00$89.5013.97%11.17%
Jan 12, 2026Robert W. Baird$95.00$89.506.15%3.54%
Dec 19, 2025UBS$140.00$70.2899.20%52.59%
Dec 11, 2025Steven SeedhouseRaymond James$110.00$65.1268.92%19.89%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 26, 2026Leerink PartnersOutperformOutperformhold
Feb 26, 2026Evercore ISIOutperformOutperformhold
Feb 26, 2026RBC CapitalOutperformOutperformhold
Feb 17, 2026RBC CapitalOutperforminitialise
Jan 20, 2026Evercore ISIOutperformOutperformhold
Jan 13, 2026H.C. WainwrightBuyBuyhold
Jan 12, 2026Cowen & Co.BuyBuyhold
Dec 19, 2025CitigroupOutperformOutperformhold
Dec 19, 2025CitigroupMarket OutperformMarket Outperformhold
Dec 11, 2025Raymond JamesStrong BuyStrong Buyhold

Financial Forecast

EPS Forecast

$-10 $-6 $-2 $2 $6 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.77$-4.01$-4.00$-1.85$-0.47---
Avg Forecast$-4.48$-4.03$-3.37$-1.62$-0.62$0.62$2.92$4.97
High Forecast$-4.10$-3.79$-3.07$-0.43$0.83$4.99$6.98$5.97
Low Forecast$-5.21$-4.65$-3.62$-1.98$-1.28$-1.13$0.49$4.54
Surprise %-38.17%-0.50%18.69%14.20%-24.19%---

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$19.14M$77.06M$186.37M$336.89M$521.31M---
Avg Forecast$78.42M$76.00M$184.64M$333.95M$422.98M$521.39M$718.97M$919.96M
High Forecast$88.19M$84.88M$186.67M$336.76M$483.39M$521.39M$830.15M$1.06B
Low Forecast$73.23M$72.47M$179.31M$332.51M$396.78M$521.39M$670.45M$857.89M
Surprise %-75.60%1.40%0.94%0.88%23.25%---

Net Income Forecast

$-250M $-140M $-30M $80M $190M $300M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-83.99M$-135.66M$-163.41M$-87.94M$-23.36M---
Avg Forecast$-183.22M$-164.93M$-136.73M$-49.23M$-36.95M$44.32M$162.92M$203.34M
High Forecast$-167.46M$-154.97M$-125.39M$-17.48M$33.78M$203.99M$285.38M$244.21M
Low Forecast$-212.90M$-189.98M$-148.08M$-80.98M$-52.35M$-46.16M$20.03M$185.50M
Surprise %-54.16%-17.74%19.51%78.64%-36.77%---

MIRM Forecast FAQ

Is Mirum Pharmaceuticals stock a buy?

Mirum Pharmaceuticals stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 17 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Mirum Pharmaceuticals is a favorable investment for most analysts.

What is Mirum Pharmaceuticals's price target?

Mirum Pharmaceuticals's price target, set by 18 Wall Street analysts, averages $116.7 over the next 12 months. The price target range spans from $95 at the low end to $140 at the high end, suggesting a potential 27.19% change from the previous closing price of $91.75.

How does Mirum Pharmaceuticals stock forecast compare to its benchmarks?

Mirum Pharmaceuticals's stock forecast shows a 27.19% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Mirum Pharmaceuticals over the past three months?

  • March 2026: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Mirum Pharmaceuticals’s EPS forecast?

Mirum Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $0.62, marking a -231.91% decrease from the reported $-0.47 in 2025. Estimates for the following years are $2.92 in 2027, and $4.97 in 2028.

What is Mirum Pharmaceuticals’s revenue forecast?

Mirum Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $521.39M, reflecting a 0.01% increase from the reported $521.31M in 2025. The forecast for 2027 is $718.97M, and $919.96M for 2028.

What is Mirum Pharmaceuticals’s net income forecast?

Mirum Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $44.32M, representing a -289.68% decrease from the reported $-23.363M in 2025. Projections indicate $162.92M in 2027, and $203.34M in 2028.